Monthly Archives: February 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Natus Medical Incorporated (BABY) and Lead Plaintiff Deadline: March 31, 2017

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ: BABY) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Natus securities between October 16, 2015 and April 3, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/baby.

The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose material adverse facts about Natus’ business, operations, and prospects, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) consequently, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis. Once this information was made known to the investing public, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/baby, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Natus, you have until March
31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454434

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) and Lead Plaintiff Deadline: March 28, 2017

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ: EGLT) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Egalet securities between December 15, 2015, and January 9, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/eglt.

The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose material adverse information about its lead product, ARYMO ER, and the likelihood that it would receive oral abuse-deterrent labeling.

On January 9, 2017, Egalet released a statement announcing the approval of its product Arymo ER. Later that day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Following this news, Egalet stock dropped, thus damaging investors.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/eglt, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Egalet, you have until March
28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 453859

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aetna Inc. (AET) and Lead Plaintiff Deadline: March 27, 2017

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Aetna Inc. (“Aetna” or the “Company”) (NYSE: AET) and certain of its officers, on behalf of shareholders who purchased Aetna securities between August 15, 2016 and January 20, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/aet.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aetna and its senior executives tried to influence Aetna’s participation in the Public Exchanges for positive treatment from regulators regarding the Humana acquisition; (2) Aetna threatened to limit its involvement in public health insurance exchanges if the Department of Justice (“DOJ”) tried to block the merger; (3) Aetna did not withdraw from certain public health insurance exchanges for business reasons as Defendants claimed, but to follow through on its threat of leaving the marketplace once the DOJ filed suit and to improve its litigation position; (4) Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and (5) consequently, Defendants’ statements regarding Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/aet, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Aetna, you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 453563

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against PixarBio Corporation (PXRB) and Lead Plaintiff Deadline – March 27, 2017

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against PixarBio Corporation (“PixarBio” or the “Company”) (OTC PINK: PXRB) and certain of its officers, on behalf of a class who purchased PixarBio securities: (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pxrb.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s statements in press releases, third-party promotional materials, and its Form S-1 regarding, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and its current and prospective development efforts lacked accuracy; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

On January 23, 2017, the SEC disclosed the temporary suspension of PixarBio trading “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company’s current and prospective development efforts.”

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/pxrb, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in PixarBio, you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 453645

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against BT Group plc (BT) and Lead Plaintiff Deadline – March 27, 2017

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against BT Group plc (“BT” or the “Company”) (NYSE: BT) and certain of its officers, on behalf of a class who purchased BT ADRs between May 23, 2013, and January 23, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/bt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) BT’s Italian division had engaged in improper accounting practices; (2) BT thus significantly overstated its earnings; (3) the above mentioned would likely cause BT to cut its revenue, earnings, and free cash flow forecasts; and (4) consequently, BT’s public statements were materially false and misleading.

In October 2016, BT exposed an initial investigation into historical accounting practices in its Italian division, resulting in several years of overstated earnings, and stated a substantial write-down. After finding this overstatement and corrupt practices in its Italian division, on January 24, 2016, BT cut its predictions of its revenue, earnings, and free cash flow for 2017 and 2018. Consequently, the write-down size on BT’s Italian business has more than doubled and the Company said that its revenue would not grow for the next two years and that its earnings guidance has been significantly reduced. “We are deeply disappointed with the improper practices which we have found in our Italian business,” Chief Executive, Gavin Patterson, said. Following this news, BT’s ADR price dropped $5.05 or 20.67%, to a closing price of $19.38 on January 24, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/bt, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in BT, you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 453628

Real Estate Agents Melbourne, FL – Dealing with Probate Real Estate Sales

Death is everywhere these days. Many people are left with burying family members who own property. A Probate Realtor is necessary when a love one passes and has property. Decisions will need to be addressed pertaining to the property.

Melbourne, United States – February 28, 2017 /PressCable/ —

Be Wise Marketing has identified over 8 Probate Real Estate agents in Melbourne region. These Real Estate agents are unique because they deal with Probate Real Estate sales, and their clients are people who are grieving and in a situation that was not planned. Probate is necessary when a love one passes and has property, but what happens after probate. A Real Estate agent will be of for assistance with the sale of the property. Whenever the owner of a house or property dies, it is of necessity that the family of the deceased take over the properties or an executor is named for the property. On several occasions, the relatives may not want to possess these properties or house. Considering this, selling a house or property can be a complex process. There is lots of procedure to follow, ranging from the legal processes to the appropriate market value of the property. There is a need for an expert to handle many of these processes in order to land on a safer ground. That is why a real estate company was established to assist a buyer or seller at every stage, from setting a price to marketing the property to closing the sale.

Click to see a top Real Estate agent in Melbourne, FL: http://bewisemarketing.com/realtor

Yvonne Moore of Be Wise Marketing has commented:

There are many turning wheels to listing a home with a realtor, but when a love one passes who owns property this is a unique situation. The Probate realtor has to be professional, caring and most of all have empathy.

Reviews of Realtors who work with Probate Real Estate sales in the region vary from bad to good reviews. Here is a list of somethings to watch out for when hiring a realtor:

The Real Estate agent is licensed for the State of Florida. Make sure the Real Estate agent is a member The National Association of REALTORS, which means that he or she must uphold the standards of the association and its code of ethics. The Real Estate agent understands the legal system dealing with Probate and Trust. The Real Estate agent is a good listener to understand the situation. The Real Estate agent is not rushing for the paperwork to be signed to them. In a Probate Real Estate sale there can be than one person on title, the Real Estate agent understands that he or she may have to deal with multiple individuals during this transaction. Make sure the Real Estate is answering all questions.

Dealing with the passing of a love one is very difficult. Yet, when there is property involved there are many decisions that will need to be discussed pertaining to the property. A Probate lawyer can answer many questions but a Probate lawyer cannot list a home if the loves ones decide to sale the home.

Purchasing a home or selling a home is a major decision in anyone’s life. Take time and choose a Real Estate agent who is knowledgeable and caring

Contact Info:
Name: Yvonne Moore
Email: yvonne@bewisemarketing.com
Organization: Be Wise Marketing
Address: 2703 Carlson Circle, Melbourne, FL 32901, United States
Phone: +1-321-247-6016

Source: PressCable

Release ID: 173827

Fascinating latest mechanical metronome to improve timing

Latest mechanical metronome designed by Tempi

Charlotte, United States – February 28, 2017 /PressCable/ —

It is very easy to differentiate between a music student who uses the metronome from a student who does not. It is very noticeable that the musicians who are accustomed to using this helpful tool, have a much better technique than those who are not. Besides, these students who have embraced the metronome to their practice, can learn with easiness and more quickly those challenging songs which normally for a typical student would take a long time to learn.

In its desire to accompany the music lovers on their path to success, Tempi decided to launch its newest sensational mechanical metronome, to help them out to achieve their goals and to exceed their expectations in regards to the music. This incredible mechanical metronome helps on developing a better finger preciseness along with an accurate sense of timing which is crucial when it comes to providing an excellent musical performance.

https://www.amazon.com/Tempi-Tem-4000-Metronome-for-Musicians/dp/B015ULU8HI

One of the biggest problems that almost every beginner and sometimes even advanced guitarist have is the lack of awareness of the beat while playing. Ideally one should feel that beat underneath any song one is playing. However many musicians can’t determine where exactly the beat is even though sometimes they are playing a rhythm correctly. To sort out all of these problems the musicians run into on a daily basis, Tempi designed the magnificent mechanical metronome, which also helps on providing a visual sense of the pulse due to the motion of its pendulum.

On top of all, this ultimate Tempi’s metronome has an exceptional and elegant design, being very attractive to any music student or professional. It’s made of durable materials such as its steel gears which ensure it will remain usable even after years of practicing with it. In addition to that, this fantastic mechanical metronome comes along with a two-year warranty, protecting the buyer against any possible defects it might have.

Contact Info:
Name: Daisy Day
Organization: Tempi LLC
Address: Charlotte NC, United States

For more information, please visit http://tempibrand.com

Source: PressCable

Release ID: 173081

INVESTOR ALERT: Monteverde & Associates PC Reminds TG Therapeutics, Inc. Shareholders To Contact The Firm Before March 7, 2017 Class Action Deadline – TGTX

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York against TG Therapeutics, Inc. (NASDAQ: TGTX) (“TG Therapeutics” or the “Company”) on behalf of purchasers of the Company’s securities between September 15, 2014 and October 12, 2016, inclusive (the “Class Period”).

The lawsuit is based on TG Therapeutics making false and/or misleading statements, as well as failing to disclose material facts about the Company’s business, and operation. In particular, TG Therapeutics made false and/or misleading statements and/or omitted material information concerning the GENUINE Phase III trial, assuring investors it was a “best-in-class treatment” that would be “successful” and “offer patients a novel chemo-free treatment option.” As a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.

Class Action Attorney Mr. Monteverde would like to personally discuss with you how to potentially recover your monetary losses, if incurred during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than March 7, 2017. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Click here for more information: http://monteverdelaw.com/securities/. It is free, and there is no cost or obligation to you.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing. Monteverde & Associates PC lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.

Contact:

Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. 59th Floor
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

SOURCE: Monteverde & Associates PC

ReleaseID: 456199

Bugout Pet Feeding System Keeps Unwanted Critters at Bay

No, You Can’t Come to Dinner

TORONTO, ON / ACCESSWIRE / February 28, 2017 / Simply Innovative Products, Inc. is pleased to announce that the Bugout Pet Feeding System is available for purchase in the North American marketplace. Bugout Pet Feeding System (Bugout) brings together simplicity and function for a carefree mealtime for your favourite furry family member. Bugout challenges standard feeding dishes by creating a simple yet innovative design to help keep critters away from your pet’s food.

How does it work? Bugout is an ant proof pet feeding system. It uses your pet’s water supply to create a moat around the removable food dish preventing unwanted dinner guests from joining in on your pet’s meal. A refillable water bottle fits securely into the system to automatically replenish your pet’s drinking water supply and moat. Bugout is proven to protect against many common crawling insects and bugs, including ants. The entire system is algae-free, non-stick, non-porous and made from high quality, FDA approved for human consumption, dishwasher safe materials.

Bugout provides a critter-free mealtime for dogs, cats, goats and turkeys alike. Bugout is an inexpensive and low maintenance solution to outdoor feeding.

The Bugout Pet Feeding System is available now for purchase globally at bugout.net. Bugout comes in two sizes; small which holds one cup of food and medium, which holds five cups. The system can be purchased for $32.99 USD including shipping for the small bowl and $36.99 USD including shipping for the medium.

To learn more: https://www.youtube.com/watch?v=gdp5lgBPPfI

The Bugout Pet Feeding System was designed by John Newman of Simply Innovative Products, Inc. Bugout is owned and operated by Simply Innovative Products. Simply Innovative Products, Inc. is based in Cheyenne, WY. The company is run by Michael Booth and John Newman. Bugout has been featured in Cat Fancy, Pet Product News, Highways Magazine and Natural Home Magazine.

About Simply Innovative Products, Inc.:

Simply Innovative Products, Inc. is a development company specializing in plastic products in various markets. Bugout TM Pet Products is the company’s latest acquisition, poised to make an impact in the multi-million dollar pet industry. Simply Innovative Products, Inc. also has a disposable lid for coffee and other beverages. Simply Lids is an award winning company whose specialty is disposable beverage lids in the food services industry. Simply Lids’ patented technologies provide safer and a more enjoyable drinking experience without splashing or spills, and has the added benefit of unique marketing opportunities, never before realized in this industry sector. Simply Lids plans on being the leader in this multi-billion dollar sector through the application of its unique technology and innovation. For more information, please visit our website at http://www.simplyinnovativeproducts.com or get social with us at www.facebook.com/bugoutpetfeedingsystem and www.twitter.com/bugoutbowl.

Toronto
info@money.ca
MONEY.CA
416-360-0000

SOURCE: Money Canada Limited

ReleaseID: 456155

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against DaVita Inc. (DVA) and Lead Plaintiff Deadline: April 3, 2017

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA) and certain of its officers, on behalf of a class who purchased DaVita securities between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/dva.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore, DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting; and (5) consequently, DaVita’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. Once true details were made known to the investing public, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/dva, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in DaVita, you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454437